Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT III: CDX-110 with Temozolomide in Newly Diagnosed GBM
NCT00458601Phase 2Completed
- Sponsor
- Celldex Therapeutics
- Start
- Aug 2007
- Primary completion
- Nov 2010
- Countries
- 1
01
Overview
A Phase 2 trial of rindopepimut in glioblastoma multiforme (GBM), sponsored by Celldex Therapeutics. Started Aug 2007; status: completed.
02
Drugs
rindopepimut
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00458601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00458601.